Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation
Abstract Aims Cardiac cachexia is a wasting syndrome characterized by chronic inflammation and high mortality. Fibroblast growth factor 21 (FGF‐21) and monocyte chemoattractant protein 1 (MCP‐1) are associated with cardiovascular disease and systemic inflammation. We investigated FGF‐21 and MCP‐1 in...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-10-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.12502 |
| _version_ | 1818275703646322688 |
|---|---|
| author | Maria Refsgaard Holm Heidi Christensen Jon Rasmussen Marie Louise Johansen Morten Schou Jens Faber Caroline Kistorp |
| author_facet | Maria Refsgaard Holm Heidi Christensen Jon Rasmussen Marie Louise Johansen Morten Schou Jens Faber Caroline Kistorp |
| author_sort | Maria Refsgaard Holm |
| collection | DOAJ |
| description | Abstract Aims Cardiac cachexia is a wasting syndrome characterized by chronic inflammation and high mortality. Fibroblast growth factor 21 (FGF‐21) and monocyte chemoattractant protein 1 (MCP‐1) are associated with cardiovascular disease and systemic inflammation. We investigated FGF‐21 and MCP‐1 in relations to cardiac function, inflammation, and wasting in patients with heart failure with reduced ejection fraction (HFrEF) and cardiac cachexia. Methods and results Plasma FGF‐21 and MCP‐1 were measured in a cross‐sectional study among the three study groups: 19 patients with HFrEF with cardiac cachexia, 19 patients with HFrEF without cachexia, and 19 patients with ischaemic heart disease and preserved ejection fraction. Patients with HFrEF and cardiac cachexia displayed higher FGF‐21 levels median (inter quantile range) 381 (232–577) pg/mL than patients with HFrEF without cachexia 224 (179–309) pg/mL and ischaemic heart disease patients 221 (156–308) pg/mL (P = 0.0496). No difference in MCP‐1 levels were found among the groups (P = 0.345). In a multivariable regression analysis, FGF‐21 (logarithm 2) was independently associated with interleukin 6 (logarithm 2) (P = 0.015) and lower muscle mass (P = 0.043), while no relation with N‐terminal pro‐hormone brain natriuretic peptide was observed. Conclusions Fibroblast growth factor 21 (FGF‐21) levels were elevated in patients with HFrEF and cardiac cachexia, which could be mediated by increased inflammation and muscle wasting rather than impaired cardiac function. |
| first_indexed | 2024-12-12T22:33:58Z |
| format | Article |
| id | doaj.art-407df2e594ac43d89abeb4c6740314f0 |
| institution | Directory Open Access Journal |
| issn | 2055-5822 |
| language | English |
| last_indexed | 2024-12-12T22:33:58Z |
| publishDate | 2019-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj.art-407df2e594ac43d89abeb4c6740314f02022-12-22T00:09:32ZengWileyESC Heart Failure2055-58222019-10-016598399110.1002/ehf2.12502Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammationMaria Refsgaard Holm0Heidi Christensen1Jon Rasmussen2Marie Louise Johansen3Morten Schou4Jens Faber5Caroline Kistorp6Centre of Endocrinology and Metabolism, Department of Internal Medicine Copenhagen University Hospitals, Herlev and Gentofte Herlev Ringvej 75 2730 Herlev DenmarkCentre of Endocrinology and Metabolism, Department of Internal Medicine Copenhagen University Hospitals, Herlev and Gentofte Herlev Ringvej 75 2730 Herlev DenmarkCentre of Endocrinology and Metabolism, Department of Internal Medicine Copenhagen University Hospitals, Herlev and Gentofte Herlev Ringvej 75 2730 Herlev DenmarkCentre of Endocrinology and Metabolism, Department of Internal Medicine Copenhagen University Hospitals, Herlev and Gentofte Herlev Ringvej 75 2730 Herlev DenmarkDepartment of Cardiology Copenhagen University Hospitals, Herlev and Gentofte Herlev DenmarkCentre of Endocrinology and Metabolism, Department of Internal Medicine Copenhagen University Hospitals, Herlev and Gentofte Herlev Ringvej 75 2730 Herlev DenmarkDepartment of Endocrinology Copenhagen University Hospitals Rigshospitalet DenmarkAbstract Aims Cardiac cachexia is a wasting syndrome characterized by chronic inflammation and high mortality. Fibroblast growth factor 21 (FGF‐21) and monocyte chemoattractant protein 1 (MCP‐1) are associated with cardiovascular disease and systemic inflammation. We investigated FGF‐21 and MCP‐1 in relations to cardiac function, inflammation, and wasting in patients with heart failure with reduced ejection fraction (HFrEF) and cardiac cachexia. Methods and results Plasma FGF‐21 and MCP‐1 were measured in a cross‐sectional study among the three study groups: 19 patients with HFrEF with cardiac cachexia, 19 patients with HFrEF without cachexia, and 19 patients with ischaemic heart disease and preserved ejection fraction. Patients with HFrEF and cardiac cachexia displayed higher FGF‐21 levels median (inter quantile range) 381 (232–577) pg/mL than patients with HFrEF without cachexia 224 (179–309) pg/mL and ischaemic heart disease patients 221 (156–308) pg/mL (P = 0.0496). No difference in MCP‐1 levels were found among the groups (P = 0.345). In a multivariable regression analysis, FGF‐21 (logarithm 2) was independently associated with interleukin 6 (logarithm 2) (P = 0.015) and lower muscle mass (P = 0.043), while no relation with N‐terminal pro‐hormone brain natriuretic peptide was observed. Conclusions Fibroblast growth factor 21 (FGF‐21) levels were elevated in patients with HFrEF and cardiac cachexia, which could be mediated by increased inflammation and muscle wasting rather than impaired cardiac function.https://doi.org/10.1002/ehf2.12502Fibroblast growth factor 21FGF‐21Monocyte chemoattractant protein 1Cardiac cachexiaMuscle wastingHeart failure with reduced ejection fraction |
| spellingShingle | Maria Refsgaard Holm Heidi Christensen Jon Rasmussen Marie Louise Johansen Morten Schou Jens Faber Caroline Kistorp Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation ESC Heart Failure Fibroblast growth factor 21 FGF‐21 Monocyte chemoattractant protein 1 Cardiac cachexia Muscle wasting Heart failure with reduced ejection fraction |
| title | Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation |
| title_full | Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation |
| title_fullStr | Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation |
| title_full_unstemmed | Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation |
| title_short | Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation |
| title_sort | fibroblast growth factor 21 in patients with cardiac cachexia a possible role of chronic inflammation |
| topic | Fibroblast growth factor 21 FGF‐21 Monocyte chemoattractant protein 1 Cardiac cachexia Muscle wasting Heart failure with reduced ejection fraction |
| url | https://doi.org/10.1002/ehf2.12502 |
| work_keys_str_mv | AT mariarefsgaardholm fibroblastgrowthfactor21inpatientswithcardiaccachexiaapossibleroleofchronicinflammation AT heidichristensen fibroblastgrowthfactor21inpatientswithcardiaccachexiaapossibleroleofchronicinflammation AT jonrasmussen fibroblastgrowthfactor21inpatientswithcardiaccachexiaapossibleroleofchronicinflammation AT marielouisejohansen fibroblastgrowthfactor21inpatientswithcardiaccachexiaapossibleroleofchronicinflammation AT mortenschou fibroblastgrowthfactor21inpatientswithcardiaccachexiaapossibleroleofchronicinflammation AT jensfaber fibroblastgrowthfactor21inpatientswithcardiaccachexiaapossibleroleofchronicinflammation AT carolinekistorp fibroblastgrowthfactor21inpatientswithcardiaccachexiaapossibleroleofchronicinflammation |